Literature DB >> 18652938

Time to foster a rational approach to preventing cardiovascular morbid events.

Jay N Cohn1, Daniel A Duprez.   

Abstract

Efforts to prevent atherosclerotic morbid events have focused primarily on risk factor prevention and intervention. These approaches, based on the statistical association of risk factors with events, have dominated clinical practice in the last generation. Because the cardiovascular abnormalities eventuating in morbid events are detectable in the arteries and heart before the development of symptomatic disease, recent efforts have focused on identifying the presence of these abnormalities as a more sensitive and specific guide to the need for therapy. Advances in noninvasive techniques for studying the vasculature and the left ventricle now provide the opportunity to use early disease rather than risk factors as the tool for clinical decision making. A disease scoring system has been developed using 10 tests of vascular and cardiac function and structure. More extensive data to confirm the sensitivity and specificity of this scoring system and to demonstrate its utility in tracking the response to therapy are needed to justify widespread application in clinical practice.

Entities:  

Mesh:

Year:  2008        PMID: 18652938     DOI: 10.1016/j.jacc.2008.02.085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertension.

Authors:  Aaron M Brody; John M Flack; Brian A Ference; Phillip D Levy
Journal:  Crit Pathw Cardiol       Date:  2014-09

Review 2.  Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.

Authors:  Pamela S Douglas; Allen Taylor; Diane Bild; Robert Bonow; Philip Greenland; Michael Lauer; Frank Peacock; James Udelson
Journal:  J Am Soc Echocardiogr       Date:  2009-07       Impact factor: 5.251

3.  Comparing Arterial Function Parameters for the Prediction of Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Elizabeth K Hom; Daniel A Duprez; David R Jacobs; David A Bluemke; Lyndia C Brumback; Joseph F Polak; Carmen A Peralta; Philip Greenland; Sheryl L Magzamen; João A C Lima; Alban Redheuil; David M Herrington; James H Stein; Dhananjay Vaidya; Pamela Ouyang; Joel D Kaufman
Journal:  Am J Epidemiol       Date:  2016-12-06       Impact factor: 4.897

4.  The problem with cardiovascular disease prevention guidelines.

Authors:  Jay N Cohn; Daniel A Duprez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

5.  Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis.

Authors:  Daniel A Duprez; David R Jacobs; Pamela L Lutsey; David A Bluemke; Lyndia C Brumback; Joseph F Polak; Carmen A Peralta; Philip Greenland; Richard A Kronmal
Journal:  Am J Epidemiol       Date:  2011-06-27       Impact factor: 4.897

6.  Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  J V Baker; N W Engen; K Huppler Hullsiek; C Stephan; M K Jain; P Munderi; S Pett; D Duprez
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

7.  Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.

Authors:  Pamela S Douglas; Allen Taylor; Diane Bild; Robert Bonow; Philip Greenland; Michael Lauer; Frank Peacock; James Udelson
Journal:  JACC Cardiovasc Imaging       Date:  2009-07

8.  Bridging the gap between public health and primary care in prevention of cardiometabolic diseases; background of and experiences with the Prevention Consultation in The Netherlands.

Authors:  Willem J J Assendelft; Markus M J Nielen; Dries M Hettinga; Victor van der Meer; Mieke van Vliet; Antonius J M Drenthen; Francois G Schellevis; Marianne J W van Oosterhout
Journal:  Fam Pract       Date:  2012-04       Impact factor: 2.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.